TY - JOUR
T1 - High mass (> 18 g) of late gadolinium enhancement on CMR imaging is associated with major cardiac events on long-term outcome in patients with biopsy-proven extracardiac sarcoidosis
AU - Agoston-Coldea, Lucia
AU - Kouaho, Sylvain
AU - Sacre, Karim
AU - Dossier, Antoine
AU - Escoubet, Brigitte
AU - Chillon, Sylvie
AU - Laissy, Jean Pierre
AU - Rouzet, François
AU - Kutty, Shelby
AU - Extramiana, Fabrice
AU - Leenhardt, Antoine
AU - Borie, Raphael
AU - Crestani, Bruno
AU - Ou, Phalla
N1 - Publisher Copyright:
© 2016 Elsevier Ireland Ltd
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Background Cardiac involvement is the most important cause of mortality in patients with systemic sarcoidosis. Late gadolinium enhancement (LGE) on cardiovascular magnetic resonance imaging (CMR) has been shown to be a predictor of major cardiovascular adverse events (MACE) in the setting of systemic sarcoidosis. We sought to evaluate the relationship between LGE mass and adverse long-term outcome in patients with biopsy-proven extracardiac sarcoidosis. Methods Between 2001 and 2013, 197 consecutive patients with suspected cardiac sarcoidosis were identified in our institution database. Of them, 56 patients have had biopsy-proven extracardiac sarcoidosis and represented our studied population. Patients were divided into two groups based on LGE mass by a median value (mild LGE < 18 g, high LGE > 18 g) for comparison of MACE. Results Twenty-eight patients had a high mass of LGE. Of them, 15 (54%) experienced MACE (OR = 31.15, 95% CI 3.7–262). Except for 1 patient, no patient with mild LGE presented with any MACE during follow-up (median of 32 months). Patients with high LGE had lower CMR-derived left (53.6 ± 14.9 vs. 62.2 ± 6.7, p < 0.01) and right (49.1 ± 11.5 vs. 56.4 ± 9.2, p < 0.05) ventricular ejection fractions. LGE mass of 18 g discriminated patients with and without MACE (93% sensitivity, 88% specificity, AUC = 0.972). LGE mass was the only independent predictor of MACE on multivariate Cox analysis adjusted (OR = 1.7, 95% CI 1.06 to 2.72, p = 0.03). Conclusion In biopsy-proven extracardiac sarcoidosis patients, a high mass of LGE > 18 g was associated with MACE.
AB - Background Cardiac involvement is the most important cause of mortality in patients with systemic sarcoidosis. Late gadolinium enhancement (LGE) on cardiovascular magnetic resonance imaging (CMR) has been shown to be a predictor of major cardiovascular adverse events (MACE) in the setting of systemic sarcoidosis. We sought to evaluate the relationship between LGE mass and adverse long-term outcome in patients with biopsy-proven extracardiac sarcoidosis. Methods Between 2001 and 2013, 197 consecutive patients with suspected cardiac sarcoidosis were identified in our institution database. Of them, 56 patients have had biopsy-proven extracardiac sarcoidosis and represented our studied population. Patients were divided into two groups based on LGE mass by a median value (mild LGE < 18 g, high LGE > 18 g) for comparison of MACE. Results Twenty-eight patients had a high mass of LGE. Of them, 15 (54%) experienced MACE (OR = 31.15, 95% CI 3.7–262). Except for 1 patient, no patient with mild LGE presented with any MACE during follow-up (median of 32 months). Patients with high LGE had lower CMR-derived left (53.6 ± 14.9 vs. 62.2 ± 6.7, p < 0.01) and right (49.1 ± 11.5 vs. 56.4 ± 9.2, p < 0.05) ventricular ejection fractions. LGE mass of 18 g discriminated patients with and without MACE (93% sensitivity, 88% specificity, AUC = 0.972). LGE mass was the only independent predictor of MACE on multivariate Cox analysis adjusted (OR = 1.7, 95% CI 1.06 to 2.72, p = 0.03). Conclusion In biopsy-proven extracardiac sarcoidosis patients, a high mass of LGE > 18 g was associated with MACE.
KW - Cardiac magnetic resonance imaging
KW - Cardiac sarcoidosis
KW - Late gadolinium enhancement
UR - http://www.scopus.com/inward/record.url?scp=84981333360&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84981333360&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2016.07.233
DO - 10.1016/j.ijcard.2016.07.233
M3 - Article
C2 - 27526366
AN - SCOPUS:84981333360
SN - 0167-5273
VL - 222
SP - 950
EP - 956
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -